Anti-VEGF Therapeutics Market – By Product, By Application, Global Forecast, 2025 – 2034

Anti-VEGF Therapeutics Market Size

The global anti-vascular endothelial growth factor (VEGF) therapeutics market size was valued at USD 13.8 billion in 2024 and is projected to exhibit 1.9% CAGR from 2025 to 2034. The increasing prevalence of eye diseases, the growing aging population, and heightened awareness and demand for treatments are driving the revenue growth in the market.
 

The rising incidence of eye diseases such as age-related macular degeneration (AMD), diabetic retinopathy, and retinal vein occlusion is a significant factor propelling the market. These conditions are associated with abnormal blood vessel growth, which VEGF inhibitors effectively target, leading to improved vision outcomes and better disease management.
 

According to the International Agency for the Prevention of Blindness (IAPB), over 196 million people worldwide are affected by AMD. Additionally, the International Diabetes Federation (IDF) reports that nearly one-third of diabetic patients globally suffer from diabetic retinopathy, reflecting the growing demand for VEGF inhibitors. With the aging population and rising diabetes rates, the market for these therapies is expected to expand significantly, driven by greater accessibility to advanced treatments.
 

Anti-VEGF therapeutics are a class of targeted biological treatments designed to inhibit the activity of vascular endothelial growth factor, a protein that promotes the formation of new blood vessels (angiogenesis). These treatments are widely used to manage diseases characterized by abnormal or excessive blood vessel formation, such as age-related macular degeneration (AMD), diabetic retinopathy, and certain cancers. By blocking VEGF, these therapies help control disease progression and alleviate symptoms associated with pathological angiogenesis, thereby augmenting the product adoption.
 

Anti-VEGF Therapeutics Market Trends

The growth of the market is being driven by several key technological advancements. The introduction of longer-acting formulations, such as Eylea and Beovu, has significantly reduced the frequency of injections needed for patients with retinal diseases. For example, Beovu offers a 12-week dosing schedule after the initial loading phase, enhancing convenience for both patients and healthcare providers.
 

• Additionally, Vabysmo, a newer anti-VEGF therapy, targets both VEGF and angiopoietin-2 (Ang-2), aiming to address multiple pathways in retinal diseases. This dual-action approach improves treatment efficacy and may require fewer injections compared to other therapies that target only VEGF.
   
• Moreover, Lucentis (ranibizumab) has been developed into newer formulations with enhanced pharmacokinetic properties, extending the duration of its therapeutic effects. The development of Lucentis biosimilars has also made treatments more cost-effective, ensuring continued patient access to effective therapies.
   
• Also, the introduction of sustained-release implants for anti-VEGF therapy, such as the development of faricimab, represents an advancement in drug delivery technology. These implants can complement existing anti-VEGF therapies like Eylea and Lucentis, potentially reducing injection frequency and improving patient outcomes.
   
• Lastly, advancements in imaging technology and diagnostics, including optical coherence tomography (OCT) and AI-based systems, allow for more precise monitoring of retinal conditions. These technologies enable healthcare providers to tailor anti-VEGF therapy regimens and optimize dosing schedules for drugs like Beovu, Lucentis, and Vabysmo. These innovations significantly contribute to the growth and effectiveness of treatments in the market.
   

Anti-VEGF Therapeutics Market Analysis

Based on product, the market is segmented into eylea, lucentis, beovu, vabysmo, and other products. The eylea segment dominates the market with a share of 46.6% in 2024.
 

• Eylea is the leading segment in the market, owing to its proven efficacy and strong clinical performance in treating age-related macular degeneration (AMD) and diabetic macular edema (DME). Eylea offers a longer dosing interval, requiring fewer injections compared to other anti-VEGF therapies, making it more convenient for both patients and healthcare providers, which has driven its widespread adoption.
   
• Also, Eylea has demonstrated strong safety and efficacy profiles across multiple clinical studies, further solidifying its position as a preferred treatment for retinal diseases and contributing to its market leadership.

Based on application, the anti-VEGF therapeutics market is segmented into macular edema, diabetic retinopathy, retinal vein occlusion, age-related macular degeneration, and myopic choroidal neovascularization. The macular edema segment dominated the market with a share of 47.5% in 2024.
 

• Macular edema is a common complication of various eye conditions, including diabetic retinopathy and retinal vein occlusion, making it a key focus for anti-VEGF therapies. The rising incidence of diabetes and related vascular diseases globally has led to an increase in macular edema cases, driving the demand for effective treatments.
   
• Moreover, the success of anti-VEGF therapies like Eylea and Lucentis in significantly reducing macular edema and improving visual outcomes has further solidified this application as a primary focus for therapeutic intervention, reinforcing its dominance in the market.

In 2024, the U.S. led the North American anti-vascular endothelial growth factor therapeutics market, generating a revenue of about USD 5.1 billion.
 

• The U.S. has a significant aging population, with AMD being one of the most common causes of vision loss. According to the American Academy of Ophthalmology, more than 2.1 million Americans are living with AMD, a number expected to grow significantly in the coming decades. The high prevalence of retinal diseases has fueled the demand for anti-VEGF therapies like Eylea, Lucentis, and Beovu, which are effective in treating these conditions.
   
• Additionally, the U.S. boasts advanced healthcare infrastructure and widespread access to cutting-edge treatments, which supports the growth of the market. With a robust healthcare reimbursement system, many patients have access to life-changing treatments, further driving market expansion.
   

The UK is set to see a robust expansion in its anti-VEGF therapeutics market from 2025 to 2034.
 

• In the UK, the rising incidence of diabetic retinopathy and AMD is contributing to the growing demand for anti-VEGF therapies. As these conditions become more prevalent, the adoption of anti-VEGF drugs like Lucentis and Eylea is expected to continue increasing.
   
• Moreover, the National Health Service (NHS), one of the largest healthcare systems globally, plays a key role in driving the adoption of anti-VEGF therapies in the UK. The NHS allocates funding for the use of cutting-edge treatments, and the availability of cost-effective anti-VEGF drugs has made them part of routine care for retinal diseases, further boosting market demand. Additionally, the UK's well-established healthcare guidelines facilitate the acceptance of innovative drugs.
   

Japan's anti-VEGF therapeutics market is set for lucrative growth from 2025 to 2034.
 

• AMD and other retinal diseases are common among the elderly, creating a large patient pool for anti-VEGF therapeutics. The Japanese government’s focus on aging-related healthcare needs has accelerated the adoption of anti-VEGF therapies to address vision loss in the aging population.
   
• Additionally, Japan has a robust regulatory framework and a history of swiftly approving new drugs, benefiting the market. The Japanese Ministry of Health, Labour and Welfare (MHLW) provides incentives for new therapies, including anti-VEGF drugs, encouraging pharmaceutical companies to introduce innovative treatments that meet the demands of the aging population.
   

Saudi Arabia's anti-VEGF therapeutics market is expected to witness substantial growth during the forecast period.
 

• Saudi Arabia has made notable progress in healthcare awareness, with rising public knowledge about eye diseases such as diabetic retinopathy and AMD. The Saudi government’s healthcare programs and initiatives are educating the population on the importance of early diagnosis and treatment, leading to higher adoption of anti-VEGF therapies.
   
• Furthermore, Saudi Arabia's Vision 2030 initiative aims to modernize healthcare infrastructure and expand patient access to advanced treatments. This includes increasing the availability of anti-VEGF drugs like Beovu, Eylea, and Lucentis in both public and private healthcare settings.
   
• The government’s investment in improving healthcare facilities and offering modern treatment options further supports the growth of the market.
   

Anti-VEGF Therapeutics Market Share

The market includes a blend of global and regional players offering a range of treatments to address the rising demand for advanced therapies in ophthalmology and oncology. Competition in this market is fuelled by technological advancements, adherence to stringent regulatory standards, and the ability to provide personalized treatments that cater to the needs of healthcare providers, including hospitals, ophthalmology clinics, and cancer centers. In emerging markets, where affordability is critical, established global companies face the challenge of offering high-quality anti-VEGF therapeutics at cost-effective prices. Regional manufacturers capitalize on this by offering more affordable alternatives, compelling global players to adjust their pricing strategies while maintaining product efficacy and regulatory compliance.
 

Anti-VEGF Market Companies

Some of the eminent market participants operating in the anti-VEGF therapeutics industry include:

• Alcon
• Amgen
• Bausch Health Companies
• Bayer
• Biogen
• Bristol-Myers Squibb
• Coherus BioSciences
• Eli Lilly and Company
• F. Hoffmann-La Roche
• Hoya Corporation
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Sanofi
• Viatris
   

Anti-VEGF Therapeutics Industry News:

• In October 2024, Roche announced positive topline results from the ELEVATUM study, a Phase IV trial evaluating the efficacy of Vabysmo (faricimab) for treating diabetic macular edema (DME) in underrepresented racial and ethnic groups. This study is significant as it focuses on populations often overlooked in clinical trials, specifically targeting those disproportionately affected by diabetes and DME.
   
• In March 2024, Regeneron published pivotal data regarding EYLEA HD (aflibercept) Injection 8 mg in The Lancet, showcasing its effectiveness in treating wet age-related macular degeneration (wAMD) and diabetic macular edema (DME).
   

The anti-VEGF therapeutics market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

Market, By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Other products

Market, By Application

• Macular edema
• Diabetic retinopathy
• Retinal vein occlusion
• Age-related macular degeneration
• Myopic choroidal neovascularization

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
• Asia Pacific 
  • China
  • Japan
  • India
  • Australia
  • South Korea
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE